Evaluation of Renal Protection by Impidapril and Irbesartan in Patients with Essential Hypertension

Evaluation of Renal Protection by Impidapril and Irbesartan in Patients with Essential Hypertension - Renal Protective Effect of Imidapril and Irbesartan

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002430

Enrollment

Registered

2009-09-02

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Interventions

imidapril 5mg or 10mg irbesartan 100mg or 200mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with hypertension based on a guideline of JSH2009

Exclusion criteria

Exclusion criteria: patients with malignancy renal failure (serum creatinine more than 3mg/dl)

Design outcomes

Primary

Measure	Time frame
clinic and home blood pressure, body weight, waist circumference, albuminuria	—

Secondary

Measure	Time frame
urinary 8OHdG, urinary NOx, adiponectin, plasma glucose, HbA1c, BNP	—

Countries

Japan

Contacts

Public ContactKen-ichi Aihara

The University of Tokushima, Graduate School of Health Biosciences Medicine and Bioregulatory Sciences

aihara@clin.med.tokushima-u.ac.jp088-633-7120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026